Tacrolimus (TAC) increases the risk of posttransplant diabetes (PTDM) compared with cyclosporine A (CYC). The present 12-month, multicenter, investigator-driven, prospective, randomized study was designed to assess whether conversion from tacrolimus to CYC can reverse PTDM after renal transplantation. Predominantly white patients with PTDM according to the 2005 American Diabetes Association criteria were randomized to either replacement of TAC with CYC or continuation of their TAC-based regimen after stratification for type of glucose-lowering therapy, steroid therapy, and hepatitis C status. At 12 months, 14 of 41 patients with complete data in the CYC arm (34%; 95%CI 19%-49%) were free of diabetes, whereas this was the case in only 4 of 39 patients (10%; 95%CI 3%-20%) in the TAC arm (P = .01). At 12 months, 39% of patients in the CYC arm were off glucose-lowering medication vs 13% of patients in the TAC arm (P = .01). The CYC group decreased glycated hemoglobin level during the 12-month follow-up, resulting in significantly lower levels compared with the TAC group (6.0 ± 0.9% vs 7.1 ± 1.7% at 12 months; P = .002). In conclusion, replacement of TAC with CYC significantly improves glucose metabolism and has the potential to reverse diabetes during 
increased cardiovascular risk, 5 patient death, 4, 6 graft dysfunction and graft loss, 4 and increased cost of patient care.
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Corticosteroids and calcineurin inhibitors (CNIs) have diabetogenic properties and contribute to the risk of PTDM. Steroids increase insulin resistance, and their avoidance has been shown to reduce the risk of PTDM. [8] [9] [10] However, early steroid withdrawal or steroid avoidance in patients receiving tacrolimus (TAC) did not reduce the risk of PTDM in a prospective and controlled trial. 11 A drawback of steroid avoidance or withdrawal is an increase in the risk of acute graft rejection. 12, 13 TAC has been associated with an increased risk of PTDM compared with cyclosporine (CYC) in multiple registry analyses, meta-analyses, and single-center cohort studies. 4, 7, [14] [15] [16] [17] In addition, the randomized DIRECT study has documented a reduction in the incidence of treated diabetes 6 months after transplantation from 17% to 9% in favor of CYC.
18
In contrast with the well-known effects of immunosuppression on PTDM rate, limited evidence has been generated on the effect of modifications in the immunosuppressive regimen on glucose metabolism in patients with established PTDM. Therefore, Kidney Disease:
Improving Global Outcomes guidelines provide an ungraded suggestion to modify the immunosuppressive regimen to reverse or ameliorate diabetes after weighing the risk of rejection or other adverse events (AEs). 19 Recent expert guidelines on the management of PTDM suggested choosing the immunosuppressive regimen based only on immunologic efficacy, regardless of associated metabolic risk.
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In an uncontrolled retrospective cohort study, the replacement of TAC with CYC resulted in the reversal of PTDM in 42% of patients, a significant reduction in insulin use, and overall better metabolic control. 20 This observation has been confirmed in several case series of kidney and liver transplant recipients. [21] [22] [23] [24] Further, replacement of TAC with CYC appears a relatively safe option for the management of PTDM as both CNIs lead to comparable long-term graft survival after renal transplantation. [25] [26] [27] [28] [29] We therefore designed the present prospective, randomized intervention trial with the primary objective to investigate whether replacement of TAC by CYC could result in diabetes reversal. Secondary efficacy outcomes were the effect of the intervention on overall glycemic control and the safety of conversion in terms of acute graft rejection and renal function.
| PATIENTS AND METHODS
The design of the trial was a multicenter nonblinded prospective, randomized, 12-month, parallel-group study. persisting on minimal or no steroids in the 3 months before inclusion.
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After providing informed consent, patients were randomized to conversion to CYC or maintenance of TAC by use of the randomization tool integrated into the study electronic case report form (eCRF) website. Randomization was stratified for (1) the type of glucose-lowering therapy patients received at the moment of randomization as a marker of the severity of diabetes (none, oral agents, insulin); (2) HCV serology (negative or positive); and (iii) steroid therapy (yes or no).
The suggested starting dosage of CYC was 2 mg/kg twice daily, which could be increased up to 3 mg/kg twice daily at the discretion of the investigator. CYC trough levels were to be maintained between 100 and 200 ng/mL (C2 levels 400-800 ng/mL) in patients receiving triple immunosuppressive therapy and between 150 and 250 ng/ mL (C2 levels 600-1000 ng/mL) in patients receiving double therapy.
Adjustments of the TAC dose were advised per protocol to attain target trough levels of 6 to 10 ng/mL in patients receiving triple and 6
to 12 ng/mL in patients receiving double immunosuppressive therapy.
TAC and CYC blood levels were measured at local laboratories in the participating centers. The bioavailability of mycophenolic acid (MPA)
is reduced in patients receiving CYC compared with those receiving TAC. 31 The dosage of MMF was recommended to be increased to 1000 mg twice daily or the dosage of enteric-coated mycophenolate sodium was recommended to be increased to 720 mg twice daily at the moment of conversion to CYC.
The primary efficacy endpoint of the study was remission of diabetes 1 year after inclusion, defined as a fasting plasma glucose level <126 mg/dL and a plasma glucose level 2 hours after a 75-g oral glucose tolerance test (OGTT) <200 mg/dL, in the absence of glucoselowering therapy. Patients taking insulin at the start of the study did not have an OGTT scheduled during the follow-up. In the latter patients and in patients who were not able to perform an OGTT at the 1-year visit (for any reason), the primary efficacy endpoint was defined as fasting plasma glucose <126 mg/dL in the absence of glucoselowering therapy.
The study addressed several prespecified secondary efficacy endpoints: The effect on overall glycemic control was investigated by measuring fasting blood glucose levels, glucose levels 2 hours after a 75-g OGTT, and glycosylated hemoglobin (HbA 1c ) levels. In addition, the dosages of insulin and different oral glucose-lowering agents were recorded, as well as the proportion of patients who stopped these treatments.
Safety of conversion was assessed in the 2 study arms by record- Follow-up study visits were scheduled at 3, 6, 9, and 12 months, with OGTT scheduled at 6 and 12 months in patients who had performed the corresponding test at baseline. All laboratory analyses were performed at the local laboratories of the participating centers. All data were recorded in the eCRFs (hosted by Medsharing, Paris, France).
The study was initially powered at 90% with a type I error of 5%
to detect a remission rate of 30% in patients randomized in the CYC arm in comparison with hypothesizing a spontaneous remission rate of 10% in the TAC arm, requiring a total sample size of 184 patients.
Because of insufficient recruitment and an overestimation of the spontaneous remission rate in the control arm, the protocol was amended in October 2009 to provide 80% power with a type I error of 5% to detect a 25% remission rate after conversion to CYC, hypothesizing a spontaneous remission rate of 5% in the control arm. In the context of this statistical hypothesis, the required sample size was 44 patients per arm, which was increased to 55 patients to compensate for possible loss of follow-up of patients in whom the outcome of interest could not be assessed due to return to dialysis, death, or withdrawal of consent. Recruitment was stopped at 87 randomized patients, which remained below the planned sample size of 110 inclusions. All patients included in the study had completed the scheduled 1-year follow-up by December 31, 2013.
| Statistical analysis
For descriptive statistics, data were summarized as proportions with 95% CIs for categorical variables, means with SDs for normally distributed continuous variables, and medians with the IQR for continuous variables that did not follow the normal distribution.
Between-group hypothesis testing of categorical variables was performed using cross-tabulation with the χ 2 test or the Fisher exact test in case of small samples, the Student t-test for normally distributed continuous variables, and the Wilcoxon rank sum test in case of lack of normal distribution.
Hypothesis testing of paired samples was realized with the Student t-test for paired samples or the Wilcoxon signed rank test.
All analyses were performed according to the intention-to-treat principle, with all patients remaining in their initial treatment allocation group regardless of subsequent changes in the immunosuppressive regimen.
| RESULTS
Between June 17, 2008, and December 20, 2012, 87 patients were recruited in the study. Two patients in the CYC arm were excluded before receiving the allocated intervention because they did not fulfill the eligibility criteria for PTDM at inclusion. One patient in the control arm withdrew consent when he was informed about allocation to the control arm ( Figure 1 ). During the course of the study, 1 patient died and 1 recipient withdrew consent in each group, leaving 41 patients in the CYC arm and 39 in the TAC arm to assess the efficacy outcomes.
| Baseline characteristics
Baseline patient characteristics of both groups were matched in terms of age, sex, body mass index, and the proportion of patients not taking steroids at inclusion (49% in both arms). Despite randomization, the number of HLA mismatches was higher in the CYC group compared with the TAC group. Patients were on average 2.5 years posttransplantation and approximately 20 months post diabetes diagnosis ( Table 1 ). The 2 study arms did not differ in baseline laboratory results ( Table 2 ).
| CNI dosage and trough levels
CYC was initiated at a mean dosage of 212 ± 100 mg/d and adjusted to a mean dosage of 177 ± 62 mg/d at 3 months. CYC trough concentrations remained stable until the end of the study (Table 3) .
Trough levels of CYC were lower than suggested per protocol during the whole follow-up period and did not differ between patients taking triple vs double immunosuppressive therapy (Table 3 ). In patients off steroids, trough concentrations were <150 ng/mL in 61% to 94% of patients and <100 ng/mL in 33% to 41% of patients (Table 3) .
Tacrolimus dose and trough concentrations remained stable and on target during the whole follow-up period (Table 3) . 
| Primary efficacy endpoint

| Secondary efficacy endpoints
Mean fasting glycemia at 12 months tended to be lower in the CYC arm (120 ± 39 mg/dL vs 138 ± 47 mg/dL in the TAC arm) without attaining statistical significance (P = .06) ( Table 4) . HbA 1c levels decreased from 6.5 ± 0.9% to 6.1 ± 0.6% in the CYC arm during the first 3 month after conversion and remained stable thereafter (Table 4) . HbA 1c levels in the TAC arm did not change during the 1-year follow-up, and the difference between the 2 arms (6.0 ± 0.9% vs 7.1 ± 1.7% in the TAC arm) was statistically significant at 12 months (P = .002). The proportion of patients with HbA 1c below the lower limit of normal (<6.0%) at the end of follow-up was 21 (51%) of 41 in the CYC arm vs 3 (8%) of 38 in the TAC arm (P < .0001; Table 4 ).
The proportion of patients receiving oral glucose-lowering agents and insulin (Table S1 ) was lower in the CYC arm at the 12-month visit without attaining statistical significance. There was no significant change in the median insulin dose in patients who remained on insulin during follow-up (Table S1 ). When taking into account both cessation of oral agents and insulin therapy, the proportion of patients without glucose-lowering therapy increased from 10 (23%) of 43 to 16 (39%) of 41 (95% CI 24%-55%) in the CYC arm. On the contrary, the proportion of patients without glucose-lowering therapy in the TAC arm decreased from 9 (22%) of 41 to 5 (13%) of 38 (95% CI 5%-30%), which was significantly lower than in the CYC arm (P = .01; Table 5 ). (Table 6 ).
| Evolution of graft function
| Lipid levels and blood pressure control
At inclusion, a higher proportion of patients allocated to the TAC arm (72% vs 45% of patients randomized to the CYC arm) were receiving lipid-lowering therapies by chance (P = .02, Table S2 ). None of the between-group comparisons in lipid levels at baseline or at 1 year were statistically significant. Conversion to CYC resulted in an approximately 10 mg/dL increase in total and LDL cholesterol (P = .013, Table S2 ). There was no effect of conversion on the control of systolic and diastolic arterial blood pressure or the use of antihypertensive medication (Table S3) .
Body mass index remained stable during follow-up without a difference between groups (Table S3 ). The study did not collect data on waist-to-hip ratio, diet, or lifestyle modifications.
| Incidence of acute rejection episodes
Four patients received treatment for acute rejection during the 12-month follow-up period: 2 in the TAC arm and 2 patients in the CYC arm (Table S4) . One acute rejection in each arm was graded as Banff "borderline," and 1 was graded as "acute cellular rejection." One patient with borderline acute rejection was switched from CYC to everolimus.
All other patients received bolus corticosteroids. In addition, 1 patient in the control group also received intravenous immunoglobulins. All acute rejection episodes were reversible, and none of the patients required therapy with anti-thymoglobulin. None of the patients returned to dialysis in the course of the study.
| Adverse events
Eighty-three AEs were reported in 27 patients in the CYC arm, and 56 AEs were reported in 24 patients in the TAC arm (Table 7 ; P = .34). There were 23 (27.7%) AEs declared as serious AEs (SAEs) in the CYC arm vs 17 (30.4%) in the TAC arm (P = .74). In the TAC arm, only 3 of 56 AEs were considered linked to the study drug. In the CYC arm, a link was considered definite in 5% of AEs and possible or probable in 14% (P = .08). The TAC dose was not modified for AEs in any patients. In the CYC arm, 2 patients stopped the drug because of AEs: 1 for gingival hyperplasia and 1 for an acute decrease in graft function. CYC dose was reduced because of AEs in 6 cases (7.2% of AEs). The numerically higher number of AEs in the CYC arm was to a large degree due to a higher incidence of infectious complications.
The increase was mainly in upper respiratory tract infections (6 in the CYC arm vs 1 in the TAC arm). Serious infectious episodes were evenly distributed, and 1 patient in each arm died because of infectious complications.
| DISCUSSION
This randomized and prospective study shows that conversion from TAC to CYC was associated with the reversal of PTDM in 34% ( Our study provides evidence in terms of resolution of diabetes, withdrawal of glucose-lowering therapy, and improved metabolic control that conversion from TAC to CYC has a beneficial effect on glucose metabolism in renal transplant recipients with PTDM. The data suggest that the effect of TAC on glucose metabolism is at least partly reversible, even in patients receiving the drug for prolonged periods of time and with a PTDM diagnosis of >1.5 years on average.
Although CYC therapy results in fewer AEs regarding glucose metabolism, it has been associated with an increased risk of hyperlipidemia and arterial hypertension. [32] [33] [34] [35] Similar to previous reports, we observed an approximately 10-mg/dL increase in total and LDL cholesterol after conversion to CYC and no significant differences in arterial blood pressure or the use of antihypertensive medication between the 2 CNIs. 18, 32 Tacrolimus trough levels were at about 8 ng/mL in both arms at inclusion and remained stable thereafter in the TAC arm. Trough levels might be considered high by current standards but are in line with target TAC exposure in renal transplant patients taking no or only low-dose steroids at the moment the study was initiated.
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The safety of low CNI exposure in patients without steroid therapy is uncertain. A recent prospective study including renal transplant patients off steroids showed that low-dose TAC was associated with a significantly increased risk of acute rejection, subclinical inflammation, and donor-specific antibodies compared with patients maintained on standard-dose TAC. 37 In this respect, it was disquieting that many patients in the CYC arm had trough concentrations below protocol targets, even in those not taking steroids. In addition, in about half of the patients, the dose of MPA was not increased after conversion to CYC as scheduled per protocol to compensate for reduced bioavailability.
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Despite the relatively low CYC exposure, no increased risk of acute rejection was observed. There were 2 episodes of acute rejection in each arm of the study during the 12-month follow-up and no graft losses from rejection. None of the patients who were converted to CYC while steroid free at inclusion developed acute rejection.
Graft function assessed based on serum creatinine and estimated glomerular filtration rate (eGFR) did not differ significantly between the 2 study arms during follow-up. eGFR decreased in both arms during the study period, but this was statistically significant only in the CYC arm.
The decrease in graft function occurred mainly early after conversion with subsequent stabilization. This is in line with previously reported reduction of graft function in patients treated with CYC. 38 Even low trough CYC concentrations are associated with a mild but significant reduction of eGFR as demonstrated in the ELiTE-Symphony trial.
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A numerically higher number of AEs were reported in patients converted to CYC. AEs occurred in slightly more than half of the patients, and a significant proportion were clustered in a small number of patients. The majority of AEs were benign and unrelated to therapy. The main difference between the 2 study arms was a nearly 2-fold increase in the number of infections. Although the difference did not reach statistical significance, a causal relationship cannot be excluded as the study was not powered to detect differences in relatively rare events.
Conversion from TAC to CYC in patients with PTDM might fit in a set of combined interventions to improve glucose metabolism that are not mutually exclusive, such as intensive insulin therapy early after transplantation, active lifestyle modification, and effective management with glucose-lowering medication. 3, 39, 40 Although conversion had a beneficial effect on glucose metabolism, our study has methodological limitations that preclude firm conclusions as to the overall risk:benefit ratio of the intervention. The main weakness of this investigator-driven study was (s)low recruitment over a 4-year period with a total recruitment that T A B L E 3 CYC and TAC dosages and trough concentrations during follow-up outcomes regardless of diabetogenicity. 3 In the light of these guidelines, larger studies with longer follow-up, providing adequate power to detect safety endpoints and to confirm the long-term benefit on glucose metabolism, are required before conversion to CYC can be formally recommended in patients with PTDM.
In conclusion, conversion from TAC to CYC causes reversal of diabetes, improved metabolic control, and reduced need for glucose-lowering therapy in a significant proportion of patients with PTDM after renal Missing data in 4 patients at 3 months and in 2 patients at 6 and 9 months. c Missing data in 1 patient at 3, 6, 9, and 12 months. None of the variability in the distribution of AEs between treatment groups attained statistical significance. CYC, cyclosporine A; TAC, tacrolimus; AE, adverse event; SAE, serious adverse event.
T A B L E 6 Creatinine and GFR estimation (MDRD) during follow-up
a Gingival hyperplasia and cyclosporine overdose.
